HealthDay News — For sorafenib-treated patients with hepatitis B virus-related hepatocellular carcinoma, antiviral therapy with nucleoside analogues is associated with improved survival, according to a study published in the Journal of Gastroenterology and Hepatology.
To evaluate the role of antiviral therapy with nucleoside analogues (NAs) in sorafenib treated patients with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC), Li Xu, MD, of the Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues conducted a retrospective cohort study with 151 patients with HBV-related HCC. Survival, progression-free survival, and adverse events in patients treated with (n=88) or without NAs (n=63) were compared.
Overall survival was significantly improved for patients treated with NAs versus those who received no NAs (medial overall survival, 16.47 versus 13.10 months; P=0.03). The risk of death was significantly reduced in patients treated with NAs versus those not receiving NAs (hazard ratio [HR], 0.67; P=0.04).
Better survival improvement was seen for patients with Barcelona Clinic Liver Cancer (BCLC) stage C and patients with higher pre-sorafenib HBV-DNA level. For HBV-related HCC patients treated with sorafenib, antiviral therapy with NAs was one of the independent prognostic factors for overall survival.
“Antiviral therapy with NAs improved overall survival of HBV-related HCC patients treated with sorafenib, especially in patients with BCLC stage C disease and higher HBV-DNA level,” concluded the study authors.